Comparison

Liraglutide vs. Petrelintide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Petrelintide
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Liraglutide and Petrelintide?: Liraglutide is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Petrelintide?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Petrelintide in Germany and the United States?: Germany: Liraglutide — Prescription, Petrelintide — Unapproved. United States: Liraglutide — Prescription, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Petrelintide

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and Petrelintide?

Liraglutide is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Petrelintide?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Petrelintide in Germany and the United States?

Germany: Liraglutide — Prescription, Petrelintide — Unapproved. United States: Liraglutide — Prescription, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.